logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.

    • Thrombopoietin Receptor Agonist class drugs

    FiltersReset Filters
    3 results

    • alvaiz

      (Eltrombopag)
      Teva Pharmaceuticals, Inc.
      Usage: ALVAIZ (eltrombopag) is indicated for treating thrombocytopenia in patients with persistent or chronic immune thrombocytopenia, chronic hepatitis C, and severe aplastic anemia who have not responded adequately to other therapies. It is not approved for myelodysplastic syndromes or with direct-acting antiviral agents for hepatitis C.

    • nplate

      (romiplostim)
      Amgen Inc
      Usage: Nplate is indicated for treating thrombocytopenia in adults and pediatric patients (1 year and older) with immune thrombocytopenia (ITP) unresponsive to other therapies. It is also used to increase survival in patients acutely exposed to myelosuppressive radiation doses. Not for thrombocytopenia due to other causes.

    • promacta

      (eltrombopag olamine)
      Novartis Pharmaceuticals Corporation
      Usage: PROMACTA is indicated for treating thrombocytopenia in patients aged 1 year and older with persistent or chronic immune thrombocytopenia unresponsive to other treatments, chronic hepatitis C to facilitate interferon therapy, and severe aplastic anemia in conjunction with immunosuppressive therapy. It is not for myelodysplastic syndromes.